AI assistant
PMV Pharmaceuticals, Inc. — Director's Dealing 2024
Jan 22, 2024
34350_dirs_2024-01-22_bd8d43b3-abfe-4ccc-85d1-daaee45c50f4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PMV Pharmaceuticals, Inc. (PMVP)
CIK: 0001699382
Period of Report: 2024-01-18
Reporting Person: Mack David Henry (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-18 | Common Stock | A | 163890 | $0.00 | Acquired | 442460 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-18 | Employee Stock Option (right to buy) | $1.80 | A | 519915 | Acquired | 2034-01-18 | Common Stock (519915) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 165307 | Indirect |
| Common Stock | 147915 | Indirect |
| Common Stock | 56978 | Indirect |
Footnotes
F1: The reported shares are represented by restricted stock units, or RSUs, all of which vest on June 30, 2025.
F2: The shares are held of record by the Stinson 2021 Irrevocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F3: The shares are held of record by The Mack-Mulligan Revocable Trust. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.
F4: Shares subject to the option vest in 48 equal monthly installments beginning on February 18, 2024.